Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability

@article{Ge2011InteractionOG,
  title={Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability},
  author={Jun Ge and Ben-Xu Tan and Ye Chen and Li Yang and Xing-Chen Peng and Hong-Ze Li and Hong-jun Lin and Yu Zhao and Meng Wei and Ke Cheng and Long-Hao Li and Hang Dong and F. Gao and Jian-ping He and Yang Wu and Meng Qiu and Yingchao Zhao and Jing-mei Su and Jian-mei Hou and Jiyan Liu},
  journal={Journal of Molecular Medicine},
  year={2011},
  volume={89},
  pages={595-602}
}
Sunitinib, a novel oral multi-targeted tyrosine kinase inhibitor for patients with metastatic renal cell carcinoma (mRCC) and advanced gastrointestinal stromal tumor, has a good prospect for clinical application and is being investigated for the potential therapy of other tumors. We observed the phenomenon that drinking tea interfered with symptom control in an mRCC patient treated with sunitinib and speculated that green tea or its components might interact with sunitinib. This study was… 

The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells

This study investigated the ability of (−)-epigallocatechin-3-gallate (EGCG) to synergize with sunitinib and inhibit insulin receptor substrate (IRS)/mitogen-activated protein kinase (MAPK) pathway activation and demonstrated marked suppression of the IRS/MAPK/p-S6K1 signaling cascade by EGCG, especially after sunit inib treatment.

The influence of green tea extract on nintedanib's bioavailability in patients with pulmonary fibrosis.

A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction

Experimental data revealed that ITs caused a general reduction in SOR bioavailability; an approximate reduction of 30% was recorded for all types of tested ITs, which indicates thatITs could affect the PK profile of SOR in rats.

Effects of green tea extract and (-)-epigallocatechin-3-gallate on pharmacokinetics of nadolol in rats.

Advances in the Antagonism of Epigallocatechin-3-gallate in the Treatment of Digestive Tract Tumors

This paper systematically summarized the research progress on the ability of EGCG to antagonize the activity and mechanism of action of digestive tract tumors, to achieve prevention, alleviation, delay, and even treat human gastrointestinal tract tumors via exogenous dietary E GCG supplementation or the development of new drugs containing EGCGs.

An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis).

The ingestion of green tea extract or its associated catechins is not expected to result in clinically significant influences on major cytochrome P450 or uridine 5'-diphospho-glucuronosyltransferase enzyme substrates or drugs serving as substrates of P-glycoprotein.

Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats

The presently reported novel food–drug interaction between E GCG and simvastatin involves the inhibition of not only CYP450 enzymes but also OATPs by EGCG.
...

References

SHOWING 1-10 OF 31 REFERENCES

Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo

Combination treatment with green tea polyphenols and celecoxib resulted in enhanced tumor growth inhibition and lowering of prostate-specific antigen levels, and circulating levels of serum insulin-like growth factor binding protein-3 compared with results of single-agent treatment.

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.

The results indicate that green tea polyphenols may have the potential to negate the therapeutic efficacy of BZM and suggest that consumption of green tea products may be contraindicated during cancer therapy with BzM.

Effects of Green Tea Compounds on Irinotecan Metabolism

Catechins are unlikely to inhibit the formation of irinotecan inactive metabolites when administered concomitantly and the induction effect of catechins on UGT1A1 seems to be modest and highly variable.

Green Tea Polyphenol Epigallocatechin-3-gallate Signaling Pathway through 67-kDa Laminin Receptor*

Findings implicate both eEF1A and MYPT1 in EGCG signaling for cancer prevention through 67LR, and it is found that e EF1A is up-regulated by E GCG through 67 LR.

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.

Evaluated EGCG efficacy in multiple myeloma demonstrated potent and specific antimyeloma activity and the rationale for its clinical evaluation was provided.

Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.

The modulations of important signaling events by EGCG are discussed and their implications in cancer management are discussed.

Effects of Repeated Green Tea Catechin Administration on Human Cytochrome P450 Activity

It is concluded that repeated green tea catechin administration is not likely to result in clinically significant effects on the disposition of drugs metabolized by CYP enzymes.

Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I–Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer

It is suggested that IGF-I/IGFBP-3 signaling pathway is a prime pathway for green tea polyphenol-mediated inhibition of prostate cancer that limits the progression of cancer through inhibition of angiogenesis and metastasis.

Synergistic inhibition of head and neck tumor growth by green tea (−)‐epigallocatechin‐3‐gallate and EGFR tyrosine kinase inhibitor

A synergistic antitumor effect of a combined treatment with EGCG and erlotinib is suggested, and provide a promising regimen for future chemoprevention and treatment of SCCHN.

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

Based on nonclinical findings, physicians prescribing sunitinib should monitor for adrenal insufficiency in patients who undergo stressors such as surgery, trauma, or severe infection, and Caution should be exercised when administering sunit inib in combination with known CYP3A4 inducers or inhibitors.